As of 2026-04-09, the Intrinsic Value of United Therapeutics Corp (UTHR) is 556.86 USD. This UTHR valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 581.69 USD, the upside of United Therapeutics Corp is -4.30%.
The range of the Intrinsic Value is 446.46 - 767.14 USD
Based on its market price of 581.69 USD and our intrinsic valuation, United Therapeutics Corp (UTHR) is overvalued by 4.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 446.46 - 767.14 | 556.86 | -4.3% |
| DCF (Growth 10y) | 540.41 - 895.60 | 663.62 | 14.1% |
| DCF (EBITDA 5y) | 612.43 - 798.94 | 700.97 | 20.5% |
| DCF (EBITDA 10y) | 689.98 - 921.63 | 797.30 | 37.1% |
| Fair Value | 692.61 - 692.61 | 692.61 | 19.07% |
| P/E | 609.03 - 735.71 | 682.29 | 17.3% |
| EV/EBITDA | 509.04 - 1,077.76 | 675.28 | 16.1% |
| EPV | 268.52 - 323.59 | 296.06 | -49.1% |
| DDM - Stable | 173.17 - 361.87 | 267.52 | -54.0% |
| DDM - Multi | 200.84 - 334.46 | 251.70 | -56.7% |
| Market Cap (mil) | 25,495.47 |
| Beta | 0.29 |
| Outstanding shares (mil) | 43.83 |
| Enterprise Value (mil) | 23,938.37 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.94% |
| Cost of Debt | 4.84% |
| WACC | 7.85% |